Dopaminergic influence on disturbed spatial discrimination in Parkinson's disease
β Scribed by Hae-Won Shin; Suk Y. Kang; Young H. Sohn
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 81 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Various sensory symptoms and disturbed sensory perception are often observed in patients with idiopathic Parkinson's disease (PD). The basis of sensory disturbance in PD is unknown but possibly reflects a role for the basal ganglia in sensory processing. To investigate the relationship between the sensory dysfunction and dopaminergic deficiency in PD, we measured spatial discrimination using the Grating Orientation Task in 21 drugβnaive patients with PD, before and after longβterm antiparkinson therapy, and 25 ageβmatched healthy controls. The grating orientation threshold was significantly higher in patients (3.03 Β± 0.84) than controls (2.03 Β± 0.79). After 3 to 10 months of antiparkinson therapy, the grating orientation threshold was significantly lowered (2.66 Β± 0.84), although it was still higher than that in controls. Improvement in the patients' sensory function was significantly correlated with motor improvement (r = 0.44). These results suggest that sensory dysfunction in Parkinson's disease is related at least in part to the dopaminergic deficit. Β© 2005 Movement Disorder Society
π SIMILAR VOLUMES
Tactile discrimination of macrogeometric objects in a two-alternative forced-choice procedure represents a demanding task involving somatosensory pathways and higher cognitive processing. The objects for somatosensory discrimination, i.e., rectangular parallelepipeds differing only in oblongness, we
## Abstract Previous studies have shown an inverse association between smoking and the prevalence of Parkinson's disease (PD), suggesting that smoking may induce a biological protection against nigral neuronal damage. In 1993, we examined the frequency of cigarette smokers among 239 patients with P
## Abstract Clinical features that are prognostic indicators of placebo response among dyskinetic Parkinson's disease patients were determined. Placeboβassociated improvements occur in Parkinsonism, but responses in dyskinesia have not been studied. Placebo data from two multicenter studies with id
## Abstract The objective of this study was to investigate neurochemical and metabolic changes in the motor cortex in a group of de novo Parkinson's disease (PD) patients before and after 6 mo treatment with the dopamine agonist pergolide. Proton magnetic resonance spectroscopy (1HβMRS) has been us